Neuren Pharmaceuticals
- Short interest
- 2.92%
- −0.09 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 3.7M
- Shares on issue
- 126.774M
Neuren Pharmaceuticals (NEU) Short Interest
Neuren Pharmaceuticals (ASX:NEU) had 2.92% of shares reported as short positions as of 8 Oct 2026, representing 3,705,096 shares. Neuren Pharmaceuticals operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.
Company profile →Neuren Pharmaceuticals (ASX:NEU) has 2.92% of its shares on issue reported as short positions as of 8 Oct 2026, or about 3,705,096 shares. Over the past 30 days that figure has fallen 0.09 percentage points, and over 90 days it has fallen 1.86 percentage points. Its highest recorded short interest was 6.51% in June 2026. NEU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads NEU today
- Zanger BreakoutWatchScore 51rank 59 of 1931
- CAN SLIMWatchScore 32rank 291 of 1541
- Minervini Trend TemplateTriggeredScore 64rank 82 of 1736
- Crowded-Short BreakoutWatchScore 34rank 110 of 1479
- Quality compoundersWatchScore 49rank 135 of 1677
Prices to 13 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
NEU fundamentals
In the half year to 30 Jun 2026, Neuren Pharmaceuticals (ASX:NEU) recorded revenue of A$42.7M and net profit after tax of A$4.9M. A year earlier it recorded revenue of A$28.3M. Year-on-year growth: revenue +51.0% (HY), EPS −86.5% (TTM). Net margin 29.1%, return on equity 5.8% (TTM). Figures are in AUD, the company's reporting currency; source: Company filing (extracted) and Yahoo Finance, as at 12 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest NEU news
All news- What Does Neuren (ASX:NEU) Gain From Europe's Rett Approval?
kalkine · 9 Oct 2026
- Are Neuren's First Dividends Landing This Week (ASX:NEU)?
kalkine · 6 Oct 2026
- Why Investors Are Keeping An Eye On Neuren Pharmaceuticals Ltd (ASX:NEU) - Kalkine
googlenews · 2 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss NEU
Start a research thread or post the first pulse update